Cargando...
SGLT inhibitors in type 1 diabetes: weighing efficacy and side effects
Even before sodium-glucose cotransporter inhibitors (SGLTi) became popular agents for the treatment of people with type 2 diabetes (T2DM), clinicians had explored their potential as adjunct therapies in type 1 diabetes (T1DM). Several trials have demonstrated improved glycemic control (compared with...
Gardado en:
| Publicado en: | Ther Adv Endocrinol Metab |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
SAGE Publications
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7383636/ https://ncbi.nlm.nih.gov/pubmed/32782777 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2042018820938545 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|